Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune‐suppressing and anticancer drugs: Just the tip of the iceberg?

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|61|2|703-711

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.61, Iss.2, 2015-02, pp. : 703-711

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression

By  

HEPATOLOGY, Vol. 61, Iss. 3, 2015-03 ,pp. : 823-833

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety assessment of niacin in the US Food and Drug Administration's mini‐sentinel system

By  

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol. 27, Iss. 1, 2018-01 ,pp. : 30-37

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of oncology drug approval between Health Canada and the US Food and Drug Administration

By  

CANCER, Vol. 121, Iss. 10, 2015-05 ,pp. : 1688-1693

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct‐acting antiviral therapy for chronic hepatitis C: Data from a national US cohort

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 25, Iss. 2, 2018-02 ,pp. : 187-197

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treating Immune‐tolerant Hepatitis B

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 2, 2015-02 ,pp. : 77-84

John Wiley & Sons Inc

Access to resources Recommend Favorite